Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.76 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.72 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.72 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3232949 | 0.95 | SRD5A2 (0.90) | SRD5A2LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL402300 | 0.93 | SRD5A2 (0.87) | SRD5A2LMNACYP1A2PTGS1SLC6A2 | |
| Monobenzone SCHEMBL1903511 | 0.87 | LMNA (1.00) | SRD5A2LMNACYP1A2PTGS1SLC6A2 | |
| Monobenzone SCHEMBL8450838 | 0.87 | LMNA (1.00) | SRD5A2LMNACYP1A2PTGS1SLC6A2 | |
| Monobenzone SCHEMBL11272996 | 0.87 | LMNA (1.00) | SRD5A2LMNACYP1A2PTGS1SLC6A2 | |
| Monobenzone SCHEMBL35631 | 0.87 | LMNA (1.00) | SRD5A2LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6654887 | 0.87 | SRD5A2 (0.77) | SRD5A2LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL8503299 | 0.87 | SRD5A2 (0.77) | SRD5A2LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL10784972 | 0.87 | SRD5A2 (0.77) | SRD5A2LMNANR4A1NR4A2NR4A3 | |
| SCHEMBL8067849 | 0.87 | SRD5A2 (0.77) | SRD5A2LMNACYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3266771-B1 | SYNTHESIS OF PHOTOACTIVABLE CAGED CYCLOFEN-OH AND DERIVATIVES THEREOF | PARIS SCIENCES LETTRES QUARTIER LATIN (FR) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017212059-A1 | SYNTHESIS OF PHOTOACTIVABLE CAGED CYCLOFEN-OH AND DERIVATIVES THEREOF | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2017-12-14 | — | — | WO | disclosed |
| WO-2016196342-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| WO-2012050263-A1 | NOVEL METHOD OF PREPARING ENDOXIFEN | CJ CHEILJEDANG CORP. (KR) | 2012-04-19 | — | — | WO | disclosed |
| US-7767739-B2 | Cyanato group-containing cyclic phosphazene compound and method for producing the same | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090170983-A1 | Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| WO-2008030771-A1 | CYCLIC ALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030771-A1 | CYCLIC ALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-13 | — | — | WO | disclosed |
| US-5693674-A | Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis | HOECHST MARION ROUSSEL, INC. (US) | 1997-12-02 | — | — | US | disclosed |
| US-5691384-A | Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0794771-A1 | METHOD OF USING TRIARYL-ETHYLENE DERIVATIVES IN THE TREATMENT AND PREVENTION OF OSTEOPOROSIS | HOECHST MARION ROUSSEL, INC. (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016646-A1 | METHOD OF USING TRIARYL-ETHYLENE DERIVATIVES IN THE TREATMENT AND PREVENTION OF OSTEOPOROSIS | HOECHST MARION ROUSSEL, INC. (US) | 1996-06-06 | — | — | WO | disclosed |
| EP-0563392-A1 | 2-PROPANOL COMPOUND AND RECORDING MATERIAL PREPARED THEREFROM | NIPPON SODA CO., LTD. (JP) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170983-A1 | Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same | CENPE, CPNE4, MCM3 | SRD5A2 2752/4885LMNA 3559/4885CYP1A2 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.